Amino acid Asp181 of 5′-flap endonuclease 1 is a useful target for chemotherapeutic development

Biochemistry

Volumn 48, Issue 42, 2009, Pages 9952-9958

  Panda, Harekrushna ^a   Jaiswal, Aruna S ^a   Corsino, Patrick E ^a   Armas, Melissa L ^a   Law, Brian K ^a   Narayan, Satya ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITE; ALKYLATING AGENTS; BASE EXCISION REPAIRS; CANCER CELLS; CHEMOTHERAPEUTIC AGENTS; COLON CANCER CELLS; COLORECTAL CANCER; COMBINATION THERAPY; CYTOTOXIC EFFECTS; DNA ALKYLATIONS; DNA REPAIR; DRUG RESISTANCE; ENDONUCLEASE ACTIVITIES; FLAP ENDONUCLEASE-1; INDUCED DAMAGE; LOW-MOLECULAR WEIGHT; METAL BINDING; MISMATCH REPAIR; MOLECULAR DOCKING; MOLECULAR INHIBITORS; SITE DIRECTED MUTAGENESIS; STRUCTURE-BASED; TEMOZOLOMIDE; THERAPEUTIC STRATEGY;

ALKYLATION; AMINATION; AMINES; AMINO ACIDS; BINDING SITES; CELLS; DNA; HYDROCARBONS; LINEAR CONTROL SYSTEMS; LINEAR MATRIX INEQUALITIES; NUCLEIC ACIDS; ORGANIC ACIDS; REPAIR;

GENES;

5' FLAP ENDONUCLEASE 1; ASPARTIC ACID DERIVATIVE; DNA; ENZYME INHIBITOR; FLAP ENDONUCLEASE; LOW MOLECULAR WEIGHT INHIBITOR; MAGNESIUM ION; NSC 281680; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; DNA ALKYLATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; EXCISION REPAIR; HUMAN; HUMAN CELL; METAL BINDING; MISMATCH REPAIR; MOLECULAR DOCKING; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

ASPARTIC ACID; COLORECTAL NEOPLASMS; DNA REPAIR; ENZYME INHIBITORS; FLAP ENDONUCLEASES; HUMANS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70350236645     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi9010754     Document Type: Article

References (32)

1. Fearon, E. R., and Vogelstein, B. (1991) A genetic model for colorectal tumorigenesis. Cell 61, 759-767.
2. Narayan, S., and Roy, D. (2003) Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol. Cancer 2, 41. (Pubitemid 38751457)
3. Liu, L., and Gerson, S. L. (2004) Therapeutic impact of methoxyamine: Blocking repair of abasic sites in the base excision repair pathway. Curr. Opin. Invest. Drugs 5, 623-627.
4. Adhikari, S., Choudhury, S., Mitra, P. S., Dubash, J. J., Sajankila, S. P., and Roy, R. (2008) Targeting base excision repair for chemo sensitization. Anticancer Agents Med. Chem. 8, 351-357.
5. Horton, J. K., and Wilson, S. H. (2003) Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency. DNA Repair 6, 530-543.
6. Hu, H. Y., Horton, J. K., Gryk, M. R., Prasad, R., Naron, J. M., Sun, D. A., Hecht, S. M., Wilson, S. H., and Mullen, G. P. (2004) Identification of small molecule synthetic inhibitors of DNA polymerase β by NMR chemical shift mapping. J. Biol. Chem. 279, 39736-39744.
7. Beard, W. A., and Wilson, S. H. (2006) Structure and mechanism of DNA polymerase β. Chem. Rev. 106, 361-382.
8. Bambara, R. A., Murante, R. S., and Henrichsen, L. A. (1997) Enzymes and reactions at the eukaryotic DNA replication fork. J. Biol. Chem. 272, 4647-4650.
9. Robins, R., Pappin, D. J. C., Wood, R. D., and Lindahl, T. (1994) Structural and functional homology between mammalian DNase IV and the 5′-nuclease domain of Escherichia coli DNA polymerase I. J. Biol. Chem. 269, 28535-28538.
10. Waga, S., Bauer, G., and Stillman, B. (1994) Reconstitution of complete SV40 DNA replication with purified replication factors. J. Biol. Chem. 269, 10923-10934.
11. 2+ and flap DNA substrate. J. Biol. Chem. 274, 1233-1239.
12. Shen, B., Nolan, J. P., Sklar, L. A., and Park, M. S. (1996) Essential amino acids for substrate binding and catalysis of human flap endonuclease 1. J. Biol. Chem. 271, 9173-9176.
13. Sakurai, S., Kitano, K., Hirito, Y., Hamada, K., Okada, K., Fukuda, K., Uchida, M., Ohtsuka, E., Morioka, H., and Hakoshima, T. (2005) Structural basis for recruitment of human flap endonuclease 1 to PCNA. EMBO J. 24, 683-693. (Pubitemid 40396099)
14. Moustakas, D. T., Lang, P. T., Pegg, S., Pettersen, E., Kuntz, I. D., Brooijmans, N., and Rizzo, R. C. (2006) Development and validation of a modular, extensible docking program: DOCK 5. J. Comput.-Aided Mol. Des. 20, 601-619.
15. Balusu, R., Jaiswal, A. S., Armas, M. L., Bloom, L. B., and Narayan, S. (2007) Structure/function analysis of the interaction of adenomatous polyposis coli (APC) with DNA polymerase β and its implications for base excision repair. Biochemistry 46, 13961-13974. (Pubitemid 350253072)
16. Narayan, S., Jaiswal, A. S., and Balusu, R. (2005) Tumor suppressor APC blocks DNA polymerase β-dependent strand displacement synthesis during long patch but not short patch base excision repair and increases sensitivity to methylmethane sulfonate. J. Biol. Chem. 280, 6942-6949.
17. Jaiswal, A. S., Balusu, R., Armas, M. L., Kundu, C. N., and Narayan, S. (2006) Mechanism of adenomatous polyposis coli (APC)-mediated blockage of long-patch base excision repair. Biochemistry 45, 15903-15914. (Pubitemid 46032511)
18. Shapiro, D. J., Sharp, P. A., Wahli, W. W., and Keller, M. J. (1988) A high-efficiency HeLa cell nuclear transcription extract. DNA7, 47-55. 19. Hait, W. N. (2009) Targeted cancer therapies. Cancer Res. 69, 1263-1267.
19. Middleton, M. R., and Margison, G. P. (2003) Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol. 4, 37-44.
20. Payne, M. J., Pratap, S. E., and Middleton, M. R. (2005) Temozolomide in the treatment of solid tumours: Current results and rationale for dosing/scheduling. Crit. Rev. Oncol. Hematol. 53, 241-252.
21. Sawyers, C. (2004) Targeted cancer therapy. Nature 432, 294-297.
22. Ding, J., Miao, Z. H., Meng, L. H., and Geng, M. Y. (2006) Emerging cancer therapeutic opportunities target DNA repair systems. Trends Pharmacol. Sci. 27, 338-344.
23. Liu, L., Markowitz, S., and Gerson, S. L. (1996) Mismatch repair mutations override alkyltransferase in conferring resistance to Temozolomide but not to 1,3-bis(2-chloroethyl) nitrosourea. Cancer Res. 56, 5375-5379. (Pubitemid 27011367)
24. Kaina, B., Christmann, M., Naumann, S., and Roos, W. P. (2007) MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair 6, 1079-1099. (Pubitemid 47058389)
25. 2+ binding site. Biochemistry 40, 3208-3214.
26. 2+ binding sites in regulation of murine flap endonuclease-1 activities. Biochemistry 41, 10323-10331.
27. Keyomarsi, K., and Pardee, A. B. (2003) Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents. Prog. Cell Cycle Res. 5, 527-532.
28. Liu, L., and Gerson, S. L. (2006) Targeted modulation of MGMT: Clinical implications. Clin. Cancer Res. 12, 328-331.
29. Kawate, H., Sakumi, K., Tsuzuki, T., Nakatsuru, Y., Ishikawa, T., Takahashi, S., Takano, H., Noda, T., and Sekiguchi, M. (1998) Separation of killing and tumorigenic effects of an alkylating agent in mice defective in two of the DNA repair genes. Proc. Natl. Acad. Sci. U.S.A. 95, 5116-5120.
30. Branch, P., Aquilina, G., Bignami, M., and Karran, P. (1993) Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362, 652-654. (Pubitemid 23962030)
31. Liu, L., Taverna, P., Hitacre, C. M., Chatterjee, S., and Gerson, S. L. (1999) Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin. Cancer Res. 5, 2908-2917.
32. Maxwell, J. A., Johnson, S. P., McLendon, R. E., Lister, D. W., Horne, K. S., Rasheed, A., Quinn, J. A., Ali Osman, F., Friedman, A. H., Modrich, P. L., Bigner, D. D., and Friedman, H. S. (2008) Mismatch repair deficiency does not mediate clinical resistance to Temozolomide in malignant glioma. Clin. Cancer Res. 14, 4859-4868.